DE60012031D1 - Piperazin verbindungen als tachykinin-antagonisten - Google Patents

Piperazin verbindungen als tachykinin-antagonisten

Info

Publication number: DE60012031D1
Authority: DE; Germany
Prior art keywords: tachykinine; antagonists; piperazin; compounds; piperazin compounds
Prior art date: 1999-10-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60012031T

Other languages

English (en)

Other versions

DE60012031T2 (de

Inventor

Giuseppe Alvaro

Fabio Romano Di

Riccardo Giovannini

Giuseppe Guercio

Yves St-Denis

Antonella Ursini

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Glaxo Group Ltd

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-07

Filing date

2000-10-05

Publication date

2004-08-12

2000-10-05 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2004-08-12 Application granted granted Critical

2004-08-12 Publication of DE60012031D1 publication Critical patent/DE60012031D1/de

2005-07-07 Publication of DE60012031T2 publication Critical patent/DE60012031T2/de

2020-10-06 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)

DE60012031T 1999-10-07 2000-10-05 Piperazin verbindungen als tachykinin-antagonisten Expired - Lifetime DE60012031T2 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB9923748		1999-10-07
GBGB9923748.9A GB9923748D0 (en)	1999-10-07	1999-10-07	Chemical compounds
PCT/EP2000/009722 WO2001025219A2 (en)	1999-10-07	2000-10-05	Piperazine compounds

Publications (2)

Publication Number	Publication Date
DE60012031D1 true DE60012031D1 (de)	2004-08-12
DE60012031T2 DE60012031T2 (de)	2005-07-07

Family

ID=10862304

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DE60042501T Expired - Lifetime DE60042501D1 (de)	1999-10-07	2000-10-05	Piperazine Verbindungen als Tachykinin-Hemmer
DE60012031T Expired - Lifetime DE60012031T2 (de)	1999-10-07	2000-10-05	Piperazin verbindungen als tachykinin-antagonisten
DE60040176T Expired - Lifetime DE60040176D1 (de)	1999-10-07	2000-10-05	Pharmazeutische Zusammenstellungen aus Tachykinin Antagonisten und einen Serotonin-Wiederaufname Hemmer

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DE60042501T Expired - Lifetime DE60042501D1 (de)	1999-10-07	2000-10-05	Piperazine Verbindungen als Tachykinin-Hemmer

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DE60040176T Expired - Lifetime DE60040176D1 (de)	1999-10-07	2000-10-05	Pharmazeutische Zusammenstellungen aus Tachykinin Antagonisten und einen Serotonin-Wiederaufname Hemmer

Country Status (33)

Country	Link
US (6)	US6951861B1 (de)
EP (3)	EP1460066B1 (de)
JP (1)	JP4776844B2 (de)
KR (2)	KR100857671B1 (de)
CN (1)	CN100413850C (de)
AR (2)	AR025975A1 (de)
AT (3)	ATE407125T1 (de)
AU (1)	AU768780B2 (de)
BR (1)	BR0014541A (de)
CA (1)	CA2386515C (de)
CO (1)	CO5251467A1 (de)
CY (2)	CY1110172T1 (de)
CZ (1)	CZ302340B6 (de)
DE (3)	DE60042501D1 (de)
DK (3)	DK1218359T3 (de)
ES (3)	ES2329130T3 (de)
GB (1)	GB9923748D0 (de)
HK (3)	HK1052506B (de)
HU (1)	HUP0203136A3 (de)
IL (2)	IL148964A0 (de)
MX (1)	MXPA02003515A (de)
MY (1)	MY130907A (de)
NO (1)	NO323776B1 (de)
NZ (2)	NZ531127A (de)
PE (1)	PE20010741A1 (de)
PL (1)	PL201191B1 (de)
PT (3)	PT1460066E (de)
SI (3)	SI1454901T1 (de)
TN (1)	TNSN00194A1 (de)
TR (1)	TR200200936T2 (de)
TW (1)	TWI225485B (de)
WO (1)	WO2001025219A2 (de)
ZA (1)	ZA200202589B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000048581A2 (en) *	1999-02-18	2000-08-24	Novartis Ag	Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases
GB9923748D0 (en) *	1999-10-07	1999-12-08	Glaxo Group Ltd	Chemical compounds
USRE39921E1 (en)	1999-10-07	2007-11-13	Smithkline Beecham Corporation	Chemical compounds
AUPQ514600A0 (en) *	2000-01-18	2000-02-10	James Cook University	Brain injury treatment
GB0003232D0 (en) *	2000-02-11	2000-04-05	Smithkline Beecham Plc	Novel composition
GB0025354D0 (en)	2000-10-17	2000-11-29	Glaxo Group Ltd	Chemical compounds
GB0108594D0 (en) *	2001-04-05	2001-05-23	Glaxo Group Ltd	Chemical compounds
GB0108595D0 (en) *	2001-04-05	2001-05-23	Glaxo Group Ltd	Chemical compounds
US20030083345A1 (en) *	2001-07-10	2003-05-01	Torsten Hoffmann	Method of treatment and/or prevention of brain, spinal or nerve injury
GB0119797D0 (en) *	2001-08-14	2001-10-03	Glaxo Group Ltd	Chemical compounds
GB0124463D0 (en)	2001-10-11	2001-12-05	Smithkline Beecham Plc	Compounds
GB0203022D0 (en) *	2002-02-08	2002-03-27	Glaxo Group Ltd	Chemical compounds
GB0203020D0 (en)	2002-02-08	2002-03-27	Glaxo Group Ltd	Chemical compounds
EP1472222A1 (de)	2002-02-08	2004-11-03	Glaxo Group Limited	Piperidylcarbonsäure amidderivate und deren verwendung zur behandlung von durch tachykinin vermittelten erkrankungen
DE10209145A1 (de) *	2002-03-01	2003-09-04	Bayer Cropscience Ag	Halogenbenzole
EP1556054A4 (de) *	2002-05-29	2007-09-05	Univ California	Antagonisierende nk1-rezeptoren hemmen den drogenmissbrauch
JP4079727B2 (ja)	2002-09-06	2008-04-23	セントラル硝子株式会社	光学活性１−（フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル）アルキルアミンｎ−モノアルキル誘導体とその製造方法
JP2006516581A (ja) *	2003-01-27	2006-07-06	グラクソ　グループ　リミテッド	機能性消化不良を治療するための化学化合物の使用
GB0308968D0 (en) *	2003-04-17	2003-05-28	Glaxo Group Ltd	Medicaments
CA2528652A1 (en) *	2003-06-19	2004-12-23	Pfizer Products Inc.	Nk1 antagonist
US20060148781A1 (en) *	2003-11-10	2006-07-06	Lundeen James E	Method and medicine for treating gastrointestinal disorder in a non-human mammal
US20060148783A1 (en) *	2003-11-10	2006-07-06	Lundeen James E	Method and medicine for treating gastrointestinal disorder including fecal incontinence
US20070142367A1 (en) *	2003-11-10	2007-06-21	Lundeen James E	Method and medicine for treating gastrointestinal disorder including fecal incontinence
US20060148782A1 (en) *	2003-11-10	2006-07-06	Lundeen James E	Method and medicine for treating a mammal presenting urinary incontinence, urinary urgency, or both
US20050113365A1 (en) *	2003-11-10	2005-05-26	Sir Isaac Newton Enterprises Llc	Method and medicine for treating gastrointestinal disorder including irritable bowel syndrome
AU2004293306B2 (en) *	2003-11-28	2008-09-25	Mitsubishi Tanabe Pharma Corporation	Piperidine compound and process for preparing the same.
WO2005068427A1 (ja) *	2004-01-14	2005-07-28	Takeda Pharmaceutical Company Limited	カルボキサミド誘導体およびその用途
DE602006015215D1 (de) *	2005-10-10	2010-08-12	Glaxo Group Ltd	Prolinamidderivate als natriumkanalmodulatoren
TW200730494A (en) *	2005-10-10	2007-08-16	Glaxo Group Ltd	Novel compounds
US20100009983A1 (en) *	2006-05-09	2010-01-14	Braincells, Inc.	5 ht receptor mediated neurogenesis
JP4904945B2 (ja)	2006-06-30	2012-03-28	セントラル硝子株式会社	光学活性１−（フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル）アルキルアミンｎ−モノアルキル誘導体の製造方法
GB0621229D0 (en) *	2006-10-20	2006-12-06	Glaxo Group Ltd	Novel use
KR20090112722A (ko)	2007-01-24	2009-10-28	글락소 그룹 리미티드	3,5-디아미노-6-(2,3-디클로로페닐)-1,2,4-트리아진 또는 ｒ(-)-2,4-디아미노-5-(2,3-디클로로페닐)-6-플루오로메틸 피리미딘 및 ｎｋ1을 포함하는 제약 조성물
JP5510040B2 (ja) *	2010-04-28	2014-06-04	セントラル硝子株式会社	光学活性（ｒ）−１−（４−フルオロフェニル）エチルアミンを得る光学分割
WO2012175434A1 (en)	2011-06-20	2012-12-27	Glaxo Group Limited	Pharmaceutical formulations comprising vestipitant
EP2729147B1 (de)	2011-07-04	2017-09-06	IRBM - Science Park S.p.A.	Nk-1 rezeptorantagonisten zur behandlung der hornhautrevaskularisierung
PL2817312T3 (pl)	2012-02-22	2016-08-31	Leo Pharma As	Nowe związki będące antagonistami receptora neurokininy 1
WO2015024203A1 (en) *	2013-08-20	2015-02-26	Leo Pharma A/S	Novel neurokinin 1 receptor antagonist compounds ii
WO2016102967A1 (en)	2014-12-23	2016-06-30	Convergence Pharmaceuticals Limited	Process for preparing alpha-carboxamide pyrrolidine derivatives
ES2813596T3 (es) *	2015-12-07	2021-03-24	Kissei Pharmaceutical	Antagonista del receptor NK1
MA51658A (fr)	2017-04-10	2020-12-02	Chase Therapeutics Corp	Association comprenant un antagoniste de nk1 et méthode de traitement de synucléinopathies
EP3645120A4 (de)	2017-06-30	2021-03-24	Chase Pharmaceuticals Corporation	Nk-1 -antagonist-zusammensetzungen und verfahren zur verwendung in der behandlung von depression
JP2020536870A (ja)	2017-10-05	2020-12-17	バイオジェンインコーポレイテッド	アルファカルボキサミドピロリジン誘導体の調製方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4219554A (en)	1974-05-09	1980-08-26	Toyama Chemical Company, Limited	Novel penicillins and cephalosporins and process for producing same
US4410522A (en)	1974-05-09	1983-10-18	Toyama Chemical Co., Ltd.	Cephalosporins
IL47168A (en)	1974-05-09	1979-07-25	Toyama Chemical Co Ltd	Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same
US4112090A (en)	1974-05-09	1978-09-05	Toyama Chemical Co., Ltd.	Novel penicillins and cephalosporins and process for producing the same
US4087424A (en)	1974-05-09	1978-05-02	Toyama Chemical Co., Ltd.	Novel penicillins and cephalosporins and process for producing the same
US4379152A (en)	1974-05-09	1983-04-05	Toyama Chemical Co., Ltd.	Cephalosporins
US4327097A (en)	1974-05-09	1982-04-27	Toyama Chemical Co., Ltd.	Novel penicillins
US4110327A (en)	1974-05-09	1978-08-29	Toyama Chemical Co., Ltd.	2,3 Diketo-piperazinocarbonylamino alkanoic acids and derivatives
NO154582C (no) *	1978-10-20	1986-11-05	Ferrosan Ab	Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
JPS57118587A (en)	1981-11-26	1982-07-23	Toyama Chem Co Ltd	Novel penicillin
US5028610A (en)	1987-03-18	1991-07-02	Sankyo Company Limited	N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
GB8709666D0 (en)	1987-04-23	1987-05-28	Beecham Group Plc	Compounds
GB8713061D0 (en)	1987-06-04	1987-07-08	Beecham Group Plc	Compounds
US5109014A (en)	1990-12-10	1992-04-28	Jacobson Richard M	N-aryl-3-aryl-4-substituted-2,3,4,5-tetrahydro-1H-pyrazole-1-carboxamides
SE9100860D0 (sv)	1991-03-22	1991-03-22	Kabi Pharmacia Ab	New use
EP0916346A3 (de)	1991-09-20	2000-12-06	Glaxo Group Limited	NK-1 Rezeptor Antagonisten und 5HT3 Rezeptor Antagonisten zur Behandlung von Emesis
CA2083891A1 (en)	1991-12-03	1993-06-04	Angus Murray Macleod	Heterocyclic compounds, compositions containing them and their use in therapy
US5563127A (en)	1993-03-24	1996-10-08	The Dupont Merck Pharmaceutical Company	Boronic acid and ester inhibitors of thrombin
US5348955A (en)	1993-06-22	1994-09-20	Merck & Co., Inc.	N,N-diacylpiperazines
IL111730A (en)	1993-11-29	1998-12-06	Fujisawa Pharmaceutical Co	Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them
IL112778A0 (en)	1994-03-04	1995-05-26	Merck & Co Inc	Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5464788A (en)	1994-03-24	1995-11-07	Merck & Co., Inc.	Tocolytic oxytocin receptor antagonists
DE4425146A1 (de)	1994-07-15	1996-01-18	Basf Ag	Verwendung heterocyclischer Verbindungen
WO1996003378A1 (fr)	1994-07-26	1996-02-08	Sankyo Company, Limited	Derives d'amide n-phenyle et d'uree
DE19520499C2 (de)	1994-09-17	2003-06-18	Boehringer Ingelheim Kg	Neurokinin-Antagonisten, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende pharmazeutische Zusammensetzungen sowie ihre Verwendung
US5696123A (en)	1994-09-17	1997-12-09	Boehringer Ingelheim Kg	Neurokinin antagonists
EP0709375B1 (de)	1994-10-25	2005-05-18	AstraZeneca AB	Therapeutisch wirksame Heterocyclen
US5998444A (en)	1995-10-24	1999-12-07	Zeneca Ltd.	Piperidinyl compounds as NK1 or NK2 antagonists
US5629322A (en)	1994-11-15	1997-05-13	Merck & Co., Inc.	Cyclic amidine analogs as inhibitors of nitric oxide synthase
US5576317A (en)	1994-12-09	1996-11-19	Pfizer Inc.	NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
US5700801A (en)	1994-12-23	1997-12-23	Karl Thomae, Gmbh	Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
MX9704745A (es)	1994-12-23	1997-10-31	Thomae Gmbh Dr K	Derivados de piperazina, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparacion.
NZ321575A (en)	1995-10-30	1999-05-28	Janssen Pharmaceutica Nv	1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
DE19608665A1 (de)	1996-03-06	1997-09-11	Boehringer Ingelheim Kg	Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6057323A (en)	1996-03-08	2000-05-02	Adolor Corporation	Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5859012A (en)	1996-04-03	1999-01-12	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
EP0891349A4 (de)	1996-04-03	2001-01-24	Merck & Co Inc	Inhibitoren von farnesylprotein-transferase
JP2000507579A (ja)	1996-04-03	2000-06-20	メルクエンドカンパニーインコーポレーテッド	ファルネシル―タンパク質トランスフェラーゼ阻害剤
AU706495B2 (en) *	1996-04-03	1999-06-17	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
AU3359697A (en)	1996-07-08	1998-02-02	Yamanouchi Pharmaceutical Co., Ltd.	Bone resorption inhibitors
ATE265209T1 (de) *	1996-07-17	2004-05-15	Merck & Co Inc	Änderung des zirkadischen rhythmus mit nicht- peptidischen neurokinin-1 rezeptor antagonisten
US6117855A (en)	1996-10-07	2000-09-12	Merck Sharp & Dohme Ltd.	Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
US5929077A (en)	1996-11-08	1999-07-27	Leftheris; Katerina	Thioproline-containing inhibitors of farnesyl protein transferase
US5977104A (en)	1996-12-02	1999-11-02	Merck Sharp & Dohme Ltd.	Use of NK-1 receptor antagonists for treating bipolar disorders
CA2273856A1 (en)	1996-12-02	1998-06-11	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating bipolar disorders
US6114315A (en)	1996-12-02	2000-09-05	Merck Sharp & Dohme Ltd.	Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
AUPO735997A0 (en)	1997-06-17	1997-07-10	Fujisawa Pharmaceutical Co., Ltd.	Piperazine derivatives
EP1014984A1 (de)	1997-08-27	2000-07-05	Merck & Co., Inc.	Prenyl-protein transferase inhibitoren
DE69824037T2 (de)	1997-11-24	2005-06-02	Merck & Co., Inc.	Beta-alanin-derivate als zell-adhäsions-inhibitoren
BR9917047A (pt) *	1998-12-14	2002-07-30	Fujisawa Pharmaceutical Co	Composto de piperazina, método para prepará-lo, composição farmacêutica contendo-o e seu uso
GB9923748D0 (en) *	1999-10-07	1999-12-08	Glaxo Group Ltd	Chemical compounds
WO2001030348A1 (en) *	1999-10-25	2001-05-03	Janssen Pharmaceutica N.V.	Use of substance p antagonists for influencing the circadian timing system
GB0025354D0 (en)	2000-10-17	2000-11-29	Glaxo Group Ltd	Chemical compounds
US20030022891A1 (en)	2000-12-01	2003-01-30	Anandan Palani	MCH antagonists and their use in the treatment of obesity
MY141736A (en)	2002-10-08	2010-06-15	Elanco Animal Health Ireland	Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists

1999
- 1999-10-07 GB GBGB9923748.9A patent/GB9923748D0/en not_active Ceased
2000
- 2000-10-05 CN CNB008158606A patent/CN100413850C/zh not_active Expired - Fee Related
- 2000-10-05 BR BR0014541-6A patent/BR0014541A/pt not_active Application Discontinuation
- 2000-10-05 JP JP2001528165A patent/JP4776844B2/ja not_active Expired - Fee Related
- 2000-10-05 MY MYPI20004668A patent/MY130907A/en unknown
- 2000-10-05 PL PL356261A patent/PL201191B1/pl unknown
- 2000-10-05 DE DE60042501T patent/DE60042501D1/de not_active Expired - Lifetime
- 2000-10-05 US US10/089,964 patent/US6951861B1/en not_active Expired - Lifetime
- 2000-10-05 EP EP04076632A patent/EP1460066B1/de not_active Expired - Lifetime
- 2000-10-05 TR TR2002/00936T patent/TR200200936T2/xx unknown
- 2000-10-05 KR KR1020077026231A patent/KR100857671B1/ko not_active IP Right Cessation
- 2000-10-05 NZ NZ531127A patent/NZ531127A/en not_active IP Right Cessation
- 2000-10-05 ES ES04076632T patent/ES2329130T3/es not_active Expired - Lifetime
- 2000-10-05 NZ NZ518144A patent/NZ518144A/xx not_active IP Right Cessation
- 2000-10-05 WO PCT/EP2000/009722 patent/WO2001025219A2/en active IP Right Grant
- 2000-10-05 SI SI200031010T patent/SI1454901T1/sl unknown
- 2000-10-05 DK DK00969414T patent/DK1218359T3/da active
- 2000-10-05 DK DK04076650T patent/DK1454901T3/da active
- 2000-10-05 DE DE60012031T patent/DE60012031T2/de not_active Expired - Lifetime
- 2000-10-05 PT PT04076632T patent/PT1460066E/pt unknown
- 2000-10-05 AT AT04076650T patent/ATE407125T1/de active
- 2000-10-05 IL IL14896400A patent/IL148964A0/xx active IP Right Grant
- 2000-10-05 KR KR1020027004438A patent/KR100817373B1/ko not_active IP Right Cessation
- 2000-10-05 ES ES00969414T patent/ES2222927T3/es not_active Expired - Lifetime
- 2000-10-05 SI SI200030492T patent/SI1218359T1/xx unknown
- 2000-10-05 SI SI200031037T patent/SI1460066T1/sl unknown
- 2000-10-05 CA CA2386515A patent/CA2386515C/en not_active Expired - Lifetime
- 2000-10-05 EP EP04076650A patent/EP1454901B1/de not_active Expired - Lifetime
- 2000-10-05 AT AT00969414T patent/ATE270664T1/de active
- 2000-10-05 DK DK04076632T patent/DK1460066T3/da active
- 2000-10-05 EP EP00969414A patent/EP1218359B1/de not_active Expired - Lifetime
- 2000-10-05 ES ES04076650T patent/ES2312917T3/es not_active Expired - Lifetime
- 2000-10-05 MX MXPA02003515A patent/MXPA02003515A/es active IP Right Grant
- 2000-10-05 DE DE60040176T patent/DE60040176D1/de not_active Expired - Lifetime
- 2000-10-05 CZ CZ20021166A patent/CZ302340B6/cs not_active IP Right Cessation
- 2000-10-05 AU AU79139/00A patent/AU768780B2/en not_active Ceased
- 2000-10-05 CO CO00075822A patent/CO5251467A1/es active IP Right Grant
- 2000-10-05 AT AT04076632T patent/ATE435215T1/de active
- 2000-10-05 PT PT00969414T patent/PT1218359E/pt unknown
- 2000-10-05 PT PT04076650T patent/PT1454901E/pt unknown
- 2000-10-05 HU HU0203136A patent/HUP0203136A3/hu unknown
- 2000-10-06 AR ARP000105284A patent/AR025975A1/es not_active Application Discontinuation
- 2000-10-06 PE PE2000001068A patent/PE20010741A1/es not_active Application Discontinuation
- 2000-10-06 TN TNTNSN00194A patent/TNSN00194A1/en unknown
- 2000-10-07 TW TW089121014A patent/TWI225485B/zh not_active IP Right Cessation
2002
- 2002-04-01 IL IL148964A patent/IL148964A/en not_active IP Right Cessation
- 2002-04-03 ZA ZA200202589A patent/ZA200202589B/en unknown
- 2002-04-05 NO NO20021637A patent/NO323776B1/no not_active IP Right Cessation
- 2002-07-03 US US10/190,170 patent/US6642240B2/en not_active Ceased
2003
- 2003-07-03 HK HK03104740.2A patent/HK1052506B/zh not_active IP Right Cessation
- 2003-08-08 US US10/637,825 patent/US7071196B2/en not_active Expired - Fee Related
2004
- 2004-05-04 US US10/838,838 patent/US20040209893A1/en not_active Abandoned
- 2004-11-06 HK HK04108748A patent/HK1065798A1/xx not_active IP Right Cessation
- 2004-12-01 HK HK04109454.6A patent/HK1066537A1/xx not_active IP Right Cessation
2006
- 2006-01-18 US US11/334,267 patent/US7345041B2/en not_active Expired - Fee Related
2007
- 2007-12-13 US US11/955,847 patent/US7625904B2/en not_active Expired - Fee Related
2008
- 2008-11-27 CY CY20081101376T patent/CY1110172T1/el unknown
2009
- 2009-09-18 CY CY20091100969T patent/CY1110104T1/el unknown
2010
- 2010-07-15 AR ARP100102567A patent/AR077414A2/es unknown

Also Published As

Publication number	Publication date
US7625904B2 (en)	2009-12-01
DK1454901T3 (da)	2009-01-12
MXPA02003515A (es)	2002-09-02
ATE435215T1 (de)	2009-07-15
ZA200202589B (en)	2003-08-27
MY130907A (en)	2007-07-31
EP1218359A2 (de)	2002-07-03
DE60040176D1 (de)	2008-10-16
TR200200936T2 (tr)	2002-07-22
PE20010741A1 (es)	2001-07-18
AU7913900A (en)	2001-05-10
AR077414A2 (es)	2011-08-24
HK1052506A1 (en)	2003-09-19
US20040048862A1 (en)	2004-03-11
CA2386515C (en)	2011-06-07
PT1460066E (pt)	2009-09-10
KR20070112308A (ko)	2007-11-22
US7071196B2 (en)	2006-07-04
US20030028021A1 (en)	2003-02-06
KR100857671B1 (ko)	2008-09-08
US20040209893A1 (en)	2004-10-21
GB9923748D0 (en)	1999-12-08
DK1460066T3 (da)	2009-11-02
US20060122192A1 (en)	2006-06-08
IL148964A0 (en)	2002-11-10
CY1110104T1 (el)	2015-01-14
EP1454901A1 (de)	2004-09-08
EP1460066B1 (de)	2009-07-01
NZ531127A (en)	2005-11-25
ATE270664T1 (de)	2004-07-15
NO20021637D0 (no)	2002-04-05
ES2312917T3 (es)	2009-03-01
NO323776B1 (no)	2007-07-02
CN100413850C (zh)	2008-08-27
SI1460066T1 (sl)	2009-12-31
CA2386515A1 (en)	2001-04-12
PT1218359E (pt)	2004-10-29
IL148964A (en)	2007-02-11
US7345041B2 (en)	2008-03-18
US6951861B1 (en)	2005-10-04
HUP0203136A2 (hu)	2003-02-28
TWI225485B (en)	2004-12-21
US20080249108A1 (en)	2008-10-09
EP1460066A1 (de)	2004-09-22
KR20020038800A (ko)	2002-05-23
CY1110172T1 (el)	2015-01-14
JP2003511377A (ja)	2003-03-25
DE60012031T2 (de)	2005-07-07
HK1065798A1 (en)	2005-03-04
EP1218359B1 (de)	2004-07-07
KR100817373B1 (ko)	2008-03-27
CO5251467A1 (es)	2003-02-28
PL356261A1 (en)	2004-06-28
SI1218359T1 (en)	2005-02-28
CZ20021166A3 (cs)	2002-11-13
US6642240B2 (en)	2003-11-04
CZ302340B6 (cs)	2011-03-23
HK1052506B (zh)	2008-12-19
AR025975A1 (es)	2002-12-26
PT1454901E (pt)	2008-12-12
EP1454901B1 (de)	2008-09-03
WO2001025219A3 (en)	2001-12-13
ES2222927T3 (es)	2005-02-16
PL201191B1 (pl)	2009-03-31
NO20021637L (no)	2002-06-06
TNSN00194A1 (en)	2005-11-10
DK1218359T3 (da)	2004-10-18
CN1391564A (zh)	2003-01-15
BR0014541A (pt)	2002-09-17
AU768780B2 (en)	2004-01-08
DE60042501D1 (de)	2009-08-13
WO2001025219A2 (en)	2001-04-12
NZ518144A (en)	2004-04-30
JP4776844B2 (ja)	2011-09-21
HUP0203136A3 (en)	2003-03-28
ATE407125T1 (de)	2008-09-15
ES2329130T3 (es)	2009-11-23
HK1066537A1 (en)	2005-03-24
SI1454901T1 (sl)	2009-02-28

Publication	Publication Date	Title
DE60012031D1 (de)	2004-08-12	Piperazin verbindungen als tachykinin-antagonisten
DE60021262D1 (de)	2005-08-18	Bizyklische heteroaromatische verbindungen als lh-agonisten
DE60112064D1 (de)	2005-08-25	Benzoamid-piperidin verbindungen als substanz p-antagonisten
ATE259363T1 (de)	2004-02-15	Piperazinderivate als 5-ht1b antagonisten
ATE283845T1 (de)	2004-12-15	Pyrimidinon verbindungen
CH1175401H1 (de)	2007-02-15	Piperazin Derivate verwendbar als CCR5 Antagonisten
ATE368658T1 (de)	2007-08-15	Hetorocyclindazole und -azaindazole verbindungen als 5-hydroxytryptamine-6 liganden
ATE253067T1 (de)	2003-11-15	Diazabicyloderivate als nikotin-acetylcholin- rezeptorliganden
IS6267A (is)	2002-02-13	Ný spíróefnasambönd
DE60031481D1 (de)	2006-12-07	Polymer-gebundene funktionelle Verbindungen
DE60039446D1 (de)	2008-08-21	Cyclische aminverbindung als ccr5 antagonist
DE60032601D1 (de)	2007-02-08	Als antikrebsmittel verwendbare heterocyklische derivate
DE60018989D1 (de)	2005-04-28	N-carbamoyloxyalkyl-substituierte azolium-verbindungen
DE60114852D1 (de)	2005-12-15	Chinazolin-derivate als alpha-1 adrenerge antagonisten
NO20015779D0 (no)	2001-11-27	Bradykinin-reseptorantagonister
ATE254621T1 (de)	2003-12-15	Thienoisoxazolyl- und thienylpyrazolyl-phenoxy substituierte propyl derivate als d4 antagonisten
ATE240954T1 (de)	2003-06-15	Oxazolidinone als 5-ht2a-antagonisten
DE60017110D1 (de)	2005-02-03	Biphenylderivate als neurokinin-1 antagonisten
DE60003072D1 (de)	2003-07-03	Thiazolidindion-derivate als antidiabetika
ATE384726T1 (de)	2008-02-15	Bicyclische heteroaromatische verbindungen
ATE241611T1 (de)	2003-06-15	Heterozyclische verbindungen als angiogenese inhibitoren
ATE264301T1 (de)	2004-04-15	Muscarin-antagonisten
ATE280161T1 (de)	2004-11-15	Imidazolverbindungen als alpha2-adrenorezeptoren antagonisten
DE60012953D1 (de)	2004-09-16	3-amino-2-phenylpiperidinderivate als substanz p antagonisten
DE69936219D1 (de)	2007-07-12	Benzothienoä3,2-cüpyridine als alpha2-antagonisten

Legal Events

Date	Code	Title	Description
2005-08-11	8364	No opposition during term of opposition